LOS ANGELES, July 29, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. 



    LIVE CALL:                        (877) 853-5636 (toll-free);
                                      international dial-in: (631) 291-
                                      4544; conference code 71719230


    WEBCAST:                          Interested parties who wish to listen
                                      to the webcast should visit the
                                      Investor Relations section of
                                      ImmunoCellular's website at
                                      www.imuc.com, under the Events and
                                      Presentations tab. A replay of the
                                      webcast will be available one hour
                                      after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com

Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

SOURCE ImmunoCellular Therapeutics, Ltd.